Shire PLC to Post Q4 2017 Earnings of $3.75 Per Share, William Blair Forecasts (SHPG)
Shire PLC (NASDAQ:SHPG) – Research analysts at William Blair reduced their Q4 2017 earnings estimates for Shire PLC in a research note issued to investors on Friday. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will earn $3.75 per share for the quarter, down from their previous forecast of $3.81.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.53 by $0.20. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.73 billion. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company’s revenue was up 54.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.38 earnings per share.
COPYRIGHT VIOLATION WARNING: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/07/shire-plc-to-post-q4-2017-earnings-of-3-75-per-share-william-blair-forecasts-shpg.html.
SHPG has been the topic of several other research reports. Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the company a “hold” rating in a research report on Wednesday, July 26th. Zacks Investment Research cut Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Sanford C. Bernstein cut Shire PLC from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $209.22 to $161.09 in a research report on Thursday, May 25th. HSBC Holdings plc cut Shire PLC from a “hold” rating to a “reduce” rating in a research report on Friday, May 19th. Finally, Goldman Sachs Group, Inc. (The) boosted their price target on Shire PLC from $202.00 to $214.00 and gave the company an “overweight” rating in a research report on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $223.18.
Shire PLC (NASDAQ:SHPG) opened at 155.91 on Monday. Shire PLC has a one year low of $155.06 and a one year high of $209.22. The firm has a market cap of $46.44 billion, a PE ratio of 159.91 and a beta of 1.60.
Several large investors have recently made changes to their positions in SHPG. Whittier Trust Co. raised its stake in shares of Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 92 shares during the period. Pinnacle Bank purchased a new stake in shares of Shire PLC during the first quarter valued at approximately $101,000. Hartford Financial Management Inc. raised its stake in shares of Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares during the period. Thompson Davis & CO. Inc. raised its stake in shares of Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 19 shares during the period. Finally, FTB Advisors Inc. raised its stake in shares of Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 75 shares during the period. 21.04% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.